Blueprint Medicines Corp Price on June 12, 2025
| BPMCDelisted Stock | USD 129.46 0.11 0.09% |
If you're considering investing in Blueprint Stock, it is important to understand the factors that can impact its price. As of today, the current price of Blueprint Medicines stands at 129.46, as last reported on the 24th of July, with the highest price reaching 129.55 and the lowest price hitting 129.30 during the day. Blueprint Medicines appears to be very steady, given 3 months investment horizon. Blueprint Medicines Corp secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18 % return per unit of risk over the last 3 months. By analyzing Blueprint Medicines' technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please makes use of Blueprint Medicines' Risk Adjusted Performance of 0.1881, downside deviation of 1.37, and Mean Deviation of 1.86 to double-check if our risk estimates are consistent with your expectations.
Blueprint Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Blueprint |
Related Headline
FibroGen Headline on 12th of June 2025
FibroGen to implement 1-for-25 reverse stock split shares do... by seekingalpha.com
FibroGen to implement 1-for-25 reverse stock split shares down 15
Blueprint Medicines Valuation on June 12, 2025
It is possible to determine the worth of Blueprint Medicines on a given historical date. On June 12, 2025 Blueprint was worth 128.03 at the beginning of the trading date compared to the closed value of 128.21. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Blueprint Medicines stock. Still, in general, we apply an absolute valuation method to find Blueprint Medicines' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Blueprint Medicines where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Blueprint Medicines' related companies.
| Open | High | Low | Close | Volume | |
| 127.97 | 128.34 | 127.83 | 127.95 | 3,826,825 | |
06/12/2025 | 128.03 | 128.26 | 127.94 | 128.21 | 4,653,922 |
| 128.18 | 128.27 | 127.95 | 127.96 | 4,731,774 |
| Backtest Blueprint Medicines | | | Blueprint Medicines History | | | Blueprint Medicines Valuation | Previous | Next |
Blueprint Medicines Trading Date Momentum on June 12, 2025
| On June 13 2025 Blueprint Medicines Corp was traded for 127.96 at the closing time. The top price for the day was 128.27 and the lowest listed price was 127.95 . The trading volume for the day was 4.7 M. The trading history from June 13, 2025 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 0.19% . The overall trading delta against the current closing price is 0.02% . |
Blueprint Medicines Corp Fundamentals Correlations and Trends
By evaluating Blueprint Medicines' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Blueprint Medicines' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Blueprint financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Blueprint Medicines Stock history
Blueprint Medicines investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Blueprint is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Blueprint Medicines Corp will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Blueprint Medicines stock prices may prove useful in developing a viable investing in Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 580 people.
Blueprint Medicines Stock Technical Analysis
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
Price Boundaries
Blueprint Medicines Period Price Range
Low | July 24, 2025
| High |
0.00 | 0.00 |
Blueprint Medicines Corp cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Blueprint Medicines July 24, 2025 Market Strength
Market strength indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By undertsting and applying Blueprint Medicines stock market strength indicators, traders can identify Blueprint Medicines Corp entry and exit signals to maximize returns
Blueprint Medicines Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Blueprint Medicines' price direction in advance. Along with the technical and fundamental analysis of Blueprint Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Blueprint to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1881 | |||
| Jensen Alpha | 0.7015 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.4128 | |||
| Treynor Ratio | 2.28 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Blueprint Stock
If you are still planning to invest in Blueprint Medicines Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Blueprint Medicines' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |